Darmiyan

Darmiyan, headquartered in San Francisco, CA, operates within the healthcare diagnostics sector, specifically focusing on neurodegenerative diseases. With a team of eight, including neuroscientists, data scientists, and healthcare experts, Darmiyan aims to revolutionize the diagnosis and treatment of brain diseases through its patented technology. This technology examines the space between brain cells to assess health and track the progression to neurodegenerative diseases. Their BrainSee Software, which has received De Novo FDA approval, offers a suite of brain tests starting with an Alzheimer’s test. These tests are designed to be highly accurate, non-invasive, and easily integrated into global healthcare systems. Darmiyan’s mission is to detect diseases like dementia early, monitor interventions, and support drug development through precise data gathered from their advanced MRI scan analysis. The company’s investors include notable entities such as Eisai, SOMPO, and Arab Angel Fund, supporting its vision to improve brain health worldwide.